The objective of this proposal is to develop techniques which will allow the use of radiolabeled monoclonal antibodies in combination with nuclear medicine imaging for in vivo detection and localization of malignant disease with the ultimate potential of utilizing these reagents to deliver therapeutic doses of 131I in the treatment of these malignancies. Our studies will concentrate on two tumor types (germ cell tumors and melanoma). We plan on utilizing monoclonal antibodies to human hCG which we have already produced and characterized as to their ability to image a human tumor implant without computerized subtraction or enhancement techniques. This agent will be tested as regards radioimaging of testicular nonseminomatous tumors and choriocarcinoma. A second and major thrust will be the development of new monoclonal reagents to tumor associated antigens on testicular cancer cells and malignant melanoma. These monoclonals will be raised to intact human tumor cells (not tumor cell lines) and screening to select appropriate antibodies will be done with freeze stored tumor and normal cells. Once antibodies are selected, their specificity will be characterized by radioimmunoassay against a variety of fresh and frozen malignant and normal human cells and tumor cell lines from various tissues. In addition, immunoperoxidase techniques will be used to examine specificity on histologic sections of normal and malignant tissue from patients. Antibodies with appropriate specificity will be purified and radiolabeled with 131I, undergo safety and molecular integrity screens and then be examined for their ability to image tumors in appropriate patient groups. Reagents which demonstrate adequate localization and radiodosimetry projections will enter Phase I/II testing for radiation therapy (131I) of cancer in appropriate patient groups. The methodology developed should be applicable to a variety of tumor types and may well provide new capabilities in the detection and therapy of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA033802-03
Application #
3171587
Study Section
(SSS)
Project Start
1983-09-30
Project End
1986-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Henry, C A; Clavo, A C; Wahl, R L (1991) Improved monoclonal antibody tumor/background ratios with exchange transfusions. Int J Rad Appl Instrum B 18:565-7
Wahl, R L (1990) Intraperitoneal delivery of monoclonal antibodies. Cancer Treat Res 51:123-49
Wahl, R L; Kaminski, M S; Ethier, S P et al. (1990) The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 31:1831-5
Liebert, M; Wahl, R L; Lawless, G et al. (1990) Direct stereotactic intracerebral injection of monoclonal antibodies and their fragments: a potential approach to brain tumor immunotherapy. Am J Physiol Imaging 5:55-9
McKeever, P E; Wahl, R L; Shakui, P et al. (1990) Products of cells from gliomas: VIII. Multiple-well immunoperoxidase assay of immunoreactivity of primary hybridoma supernatants with human glioma and brain tissue and cultured glioma cells. J Histochem Cytochem 38:815-22
Wahl, R L; Wissing, J; del Rosario, R et al. (1990) Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 31:84-9
Barrett, J S; Wahl, R L; Wagner, J G et al. (1990) Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat. Cancer Immunol Immunother 31:365-72
Wahl, R L; Wissing, J R; Kaminski, M S (1989) Isotype switch variant anti-idiotype monoclonal antibodies: comparative radiolabeling and in vitro binding. J Nucl Med 30:227-32
Himmelsbach, M; Wahl, R L (1989) Studies on the metabolic fate of 111In-labeled antibodies. Int J Rad Appl Instrum B 16:839-45
Wahl, R L; Barrett, J; Geatti, O et al. (1988) The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 26:187-201

Showing the most recent 10 out of 18 publications